Related Experiment Video
Updated: Jun 18, 2026
11:13
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Catumaxomab: a bispecific trifunctional antibody
M Sebastian1, A Kuemmel, M Schmidt
1Department of Internal Medicine III, Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. martin.sebastian@ukmainz.de
Drugs of Today (Barcelona, Spain : 1998)
|November 21, 2009
Summary
Catumaxomab, a trifunctional antibody targeting EpCAM and CD3, effectively eliminates EpCAM-positive tumor cells. This immunotherapy is approved for malignant ascites in patients with epithelial tumors, offering a new treatment option.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Catumaxomab is a trifunctional bispecific monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) and CD3.
- EpCAM is a tumor-associated antigen highly expressed in various carcinomas, often linked to poor prognosis in breast cancer.
- Catumaxomab's Fc-fragment facilitates binding to accessory immune cells, enhancing tumor cell killing.
Purpose of the Study:
- To review preclinical and clinical findings of catumaxomab.
- To discuss its efficacy and administration routes in various cancer indications.
- To highlight its role in treating EpCAM-positive epithelial tumors.
Main Methods:
- Review of existing preclinical data.
- Analysis of clinical trial results.
- Discussion of different administration routes and their outcomes.
Main Results:
- Catumaxomab mediates specific killing of EpCAM-expressing tumor cells via T-cell engagement and accessory cell activation.
- The antibody has shown efficacy in treating malignant ascites in EpCAM-positive epithelial tumors.
- Preclinical and clinical data support various administration routes for catumaxomab.
Conclusions:
- Catumaxomab represents a promising trifunctional antibody therapy for EpCAM-positive epithelial cancers.
- Its mechanism involves direct tumor cell targeting and immune cell recruitment for enhanced cytotoxicity.
- Further research and application in diverse clinical settings are warranted.
